de Andrade Enrico, de Mesquita Alexandre A, Claro Joaquim de Almeida, de Andrade Priscila M, Ortiz Valdemar, Paranhos Mário, Srougi Miguel
Sector of Sexual Medicine, Division of Urological Clinic of Sao Paulo University, Sao Paulo, Brazil.
Asian J Androl. 2007 Mar;9(2):241-4. doi: 10.1111/j.1745-7262.2007.00210.x. Epub 2006 Jul 11.
To examine the treatment efficacy of Korean Red Ginseng (KRG) in impotent men with erectile dysfunction (ED).
A total of 60 patients presenting mild or mild to moderate ED were enrolled in a double-blind, placebo-controlled study in which the efficacies of KRG and a placebo were compared. The patients received either 1,000 mg (3 times daily) of KRG or a placebo.
The five-item version of the International Index of Erectile Function (IIEF-5) score after the treatment was significantly higher in the KRG group compared with that before the treatment (from 16.4 +/- 2.9 to 21.0 +/- 6.3, P < 0.0001). In contrast, there was no difference before and after the treatment in the placebo group (from 17.0 +/- 3.1 to 17.7 +/- 5.6, P > 0.05). In the KRG group, 20 patients (66.6%), reported improved erection, significant in the global efficacy question (P < 0.01); in the placebo group there was no significance. Scores on questions 2 (rigidity), 3 (penetration), 4 and 5 (maintenance), were significantly higher for KRG than those for the placebo when those questions were answered after 12 weeks of each treatment (P < 0.01). When the score in the KRG group was compared to the placebo group after the treatment, there was a significant improvement in total score (IIEF-5 score) in questions 3 and 5 for the KRG-treated group (P < 0.001 and P < 0.0001, respectively). The levels of serum testosterone, prolactine and cholesterol after the treatment were not statistically significant different between the KRG and the placebo group (P > 0.05).
Our data show that KRG can be an effective alternative to the invasive approaches for treating male ED.
研究高丽参(KRG)对患有勃起功能障碍(ED)的阳痿男性的治疗效果。
共有60例轻度或轻度至中度ED患者参与了一项双盲、安慰剂对照研究,比较了KRG和安慰剂的疗效。患者分别接受1000毫克(每日3次)的KRG或安慰剂。
治疗后,KRG组的国际勃起功能指数(IIEF-5)五项评分显著高于治疗前(从16.4±2.9提高到21.0±6.3,P<0.0001)。相比之下,安慰剂组治疗前后无差异(从17.0±3.1到17.7±5.6,P>0.05)。在KRG组中,20例患者(66.6%)报告勃起功能改善,在总体疗效问题上具有显著性(P<0.01);安慰剂组则无显著性。在每种治疗12周后回答问题时,KRG组在问题2(硬度)、3(插入)、4和5(维持)上的得分显著高于安慰剂组(P<0.01)。治疗后将KRG组的得分与安慰剂组进行比较,KRG治疗组在问题3和5的总分(IIEF-5评分)上有显著改善(分别为P<0.001和P<0.0001)。治疗后,KRG组和安慰剂组的血清睾酮、催乳素和胆固醇水平在统计学上无显著差异(P>0.05)。
我们的数据表明,KRG可以作为治疗男性ED的侵入性方法的有效替代方案。